P-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: Correlations with cell fusion and doxorubicin resistance

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Yang, Ji Y ^a   Ha, Seon Ah ^a   Yang, Yun Sik ^b   Kim, Jin W ^a  

^a The Catholic University of Korea   (South Korea)

^b Wonkwang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FAS ANTIGEN; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 6; MULTIDRUG RESISTANCE PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN ABCB5; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; Y BOX BINDING PROTEIN 1; ABCB5 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; NUCLEAR PROTEIN; TUMOR MARKER; YBX1 PROTEIN, HUMAN;

ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL DEDIFFERENTIATION; CELL FUSION; CELL HETEROGENEITY; CELL POPULATION; CELL STRAIN MCF 7; CELL STRUCTURE; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENOMIC INSTABILITY; HETEROKARYON; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; BREAST TUMOR; DNA MICROARRAY; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL FUSION; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 77954765542     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-388     Document Type: Article

References (43)

1. Jasmin C, Gil-Delgado MA, Marino JP, Ecstein E, Descorps-Declere A, Misset JL. Phase I-II constant infusion of adriamycin (doxorubicin) by ambulatory pump delivery system in heavily pretreated (including adriamycin) breast cancer patients. Ann Oncol 1990, 1:189-193.
2. White SC, Lorigan P, Middleton MR, Anderson H, Valle J, Summers Y, Burt PA, Arance A, Stout R, Thatcher N. Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma. Cancer 2001, 92:601-608. 10.1002/1097-0142(20010801)92:3<601::AID-CNCR1360>3.0.CO;2-K, 11505405.
3. Kruh GD. Introduction to resistance to anticancer agents. Oncogene 2003, 22:7262-7264. 10.1038/sj.onc.1206932, 14576836.
4. O'Driscoll L, Clynes M. Molecular markers of multiple drug resistance in breast cancer. Chemotherapy 2006, 52:125-129. 10.1159/000092540, 16612055.
5. Clarke R, Dickson RB, Brünner N. The process of malignant progression in human breast cancer. Ann Oncol 1990, 1:401-407.
6. Coley HM. Mechanisms and consequences of chemotherapy resistance in breast cancer. Eur J Cancer 2009, (Supplements 7):3-7.
7. Langley RR, Fidler IJ. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev 2007, 28:297-321. 10.1210/er.2006-0027, 17409287.
8. Struckhoff AP, Bittman R, Burow ME, Clejan S, Elliott S, Hammond T, Tang Y, Beckman BS. Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J Pharmacol Exp Ther 2004, 309:523-532. 10.1124/jpet.103.062760, 14742741.
9. Duesberg P, Li R, Sachs R, Fabarius A, Upender MB, Hehlmann R. Cancer drug resistance: The central role of the karyotype. Drug Resist Update 2007, 10:51-58.
10. Jacobsen BM, Harrell JC, Jedlicka P, Borges VF, Varella-Garcia M, Horwitz KB. Spontaneous fusion with, and transformation of mouse stroma by, malignant human breast cancer epithelium. Cancer Res 2006, 66:8274-8279. 10.1158/0008-5472.CAN-06-1456, 16912208.
11. Bjerregaard B, Holck S, Christensen IJ, Larsson LI. Syncytin is involved in breast cancer endothelial cell fusions. Cell Mol Life Sci 2006, 63:1906-1911. 10.1007/s00018-006-6201-9, 16871371.
12. Pochampally RR, Neville BT, Schwarz EJ, Li MM, Prockop DJ. Rat adult stem cells (marrow stromal cells) engraft and differentiate in chick embryos without evidence of cell fusion. Proc Natl Acad Sci USA 2004, 101:9282-9285. 10.1073/pnas.0401558101, 438968, 15197249.
13. Ogle BM, Cascalho M, Platt JL. Biological implications of cell fusion. Nat Rev Mol Cell Biol 2005, 6:567-575. 10.1038/nrm1678, 15957005.
14. Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res 2008, 10:R86. 10.1186/bcr2156, 2614522, 18925950.
15. Bergmann S, Royer-Pokora B, Fietze E, Jürchott K, Hildebrandt B, Trost D, Leenders F, Claude JC, Theuring F, Bargou R, Dietel M, Royer HD. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res 2005, 65:4078-4087. 10.1158/0008-5472.CAN-04-4056, 15899797.
16. Kohno K, Sato S, Uchiumi T, Takano H, Kato S, Kuwano M. Tissue-specific enhancer of the human multidrug-resistance (MDR 1) gene. J Biol Chem 1990, 265:19690-19696.
17. Chen Y, Simon SM. In situ biochemical demonstration that p-Glycoprotein is a drug efflux pump with broad specificity. J Cell Biol 2000, 148:863-870. 10.1083/jcb.148.5.863, 2174548, 10704438.
18. Grant R, James W. Ironside glutathione S-transferases and cytochrome P450 detoxifying enzyme distribution in human cerebral glioma. J Neurooncol 1995, 25:1-7. 10.1007/BF01054717, 8523085.
19. Bart J, Hollema H, Groen HJ, de Vries EG, Hendrikse NH, Sleijfer DT, Wegman TD, Vaalburg W, van der Graaf WT. The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur J Cancer 2004, 40:2064-2070. 10.1016/j.ejca.2004.05.010, 15341980.
20. Bradbury PA, Middleton MR. DNA repair pathways in drug resistance in melanoma. Anticancer Drugs 2004, 15:421-426. 10.1097/01.cad.0000127665.74096.93, 15166615.
21. Kim IJ, Bae YT, Kim SJ, Kim YK, Kim DS, Lee JS. Determination and prediction of p-glycoprotein and multidrug-resistance-related protein expression in breast cancer with double-phase technetium-99 m sestamibi scintimammography. Oncology 2006, 70:403-410. 10.1159/000098812, 17237619.
22. Frank NY, Pendse SS, Lapchak PH, Margaryan A, Shlain D, Doeing C, Sayegh MH, Frank MH. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem 2003, 278:47156-47165. 10.1074/jbc.M308700200, 12960149.
23. Järvinen TA, Tanner M, Rantanen V, Bärlund M, Borg A, Grénman S, Isola J. Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000, 156:839-847. 1876829, 10702400.
24. Hembruff SL, Laberge ML, Villeneuve DJ, Guo B, Veitch Z, Cecchetto M, Parissenti AM. Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance. BMC Cancer 2008, 8:318. 10.1186/1471-2407-8-318, 2596802, 18980695.
25. Yahata H, Kobayashi H, Kamura T, Amada S, Hirakawa T, Kohno K, Kuwano M, Nakano H. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J Cancer Res Clin Oncol 2002, 128:621-626. 10.1007/s00432-002-0386-6, 12458343.
26. Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJA. The origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 2005, 5:899-904. 10.1038/nrc1740, 16327766.
27. Müller I, Jenner A, Bruchelt G, Niethammer D, Halliwell B. Effect of concentration on the cytotoxic mechanism of doxorubicin-apoptosis and oxidative DNA damage. Biochem Biophys Res Commun 1997, 230:2254-2257.
28. Wu J, Lee C, Yokom D. Disruption of the Y-box binding protein-1 (YB-1) results in suppression of the epidermal growth factor receptor and Her-2. Cancer Res 2006, 66:4872-4879. 10.1158/0008-5472.CAN-05-3561, 16651443.
29. Stratford AL, Habibi G, Astanehe A, Jiang H, Hu K, Park E, Shadeo A, Buys TP, Lam W, Pugh T, Marra M, Nielsen TO, Klinge U, Mertens PR, Aparicio S, Dunn SE. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer providing a potential target for therapy. Breast Cancer Res 2007, 9:R61. 10.1186/bcr1767, 2242657, 17875215.
30. Persson K, Pandis N, Mertens F, Borg A, Baldetorp B, Killander D, Isola J. Chromosomal aberrations in breast cancer: a comparison between cytogenetics and comparative genomic hybridization. Gene Chromosome Canc 1999, 25:115-122.
31. Boveri T. Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris. J Cell Sci 2008, 121(Suppl 1):1-84. 10.1242/jcs.025742, 18089652.
32. Loeb KR, Loeb LA. Genetic instability and the mutator phenotype studies in ulcerative colitis. Am J Pathol 1999, 154:1621-1626. 1866616, 10362784.
33. Gollin SM. Chromosomal instability. Curr Opin Oncol 2004, 16:25-31. 10.1097/00001622-200401000-00006, 14685089.
34. Gerlach JH, Bell DR, Karakousis C, Slocum HK, Kartner N, Rustum YM, Ling V, Baker RM. P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol 1987, 5:1452-1460.
35. Giguère L, Morals R. On suppression of tumorigenicity in hybrid and cybrid mouse cells. Somat Cell Genet 1981, 7:457-471. 10.1007/BF01542990, 7280931.
36. Duelli D, Lazebnik Y. Cell fusion: A hidden enemy?. Cancer Cell 2003, 3:445-448. 10.1016/S1535-6108(03)00114-4, 12781362.
37. Wang L, Zhou P, Craig RW, Lu L. Protection from cell death by mcl-1 is mediated by membrane hyperpolarization induced by K(+) channel activation. J Membr Biol 1999, 172:113-120. 10.1007/s002329900589, 10556359.
38. Bose R, Lam HYP. Membrane transport changes in an adriamycin-resistant murine leukemia cell line and in its sensitive parental cell line. Cancer Chemoth Pharm 1988, 21:14-18.
39. Cho HC, Kashiwakura Y, Marbán E. Creation of a biological pacemaker by cell fusion. Circ Res 2007, 100:1112-1115. 10.1161/01.RES.0000265845.04439.78, 17395872.
40. Robinson MJ, Xu Be BE, Stippec S, Cobb MH. Different domains of the mitogen-activated protein kinases ERK3 and ERK2 direct subcellular localization and upstream specificity in vivo. J Biol Chem 2002, 277:5094-5100. 10.1074/jbc.M110935200, 11741894.
41. Khokhlatchev AV, Canagarajah B, Wilsbacher J, Robinson M, Atkinson M, Goldsmith E, Cobb MH. Phosphorylation of the MAP Kinase ERK2 promotes its homodimerization and nuclear translocation. Cell 1998, 93:605-615. 10.1016/S0092-8674(00)81189-7, 9604935.
42. Kikyo N, Wolffe AP. Reprogramming nuclei: insights from cloning, nuclear transfer and heterokaryons. J Cell Sci 2000, 113:11-20.
43. Pawelek JM. Tumor cell fusion as a source of myeloid traits in cancer. Lancet Oncol 2005, 6:988-993. 10.1016/S1470-2045(05)70466-6, 16321767.